Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Key facts

Sponsor

Adverum Biotechnologies, Inc.

Principal Investigator

Charlton Strange, MD

Medical University of South Carolina, Charleston, SC, USA

Intervention

ADVM-043(genetic)

Enrollment

6 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2019

Study locations (2)

• University of Florida, Gainesville, Florida, United States
• Medical University of South Carolina, Charleston, South Carolina, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07431112
  A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
  AIRNA Corporation
• RECRUITINGPHASE4NCT07135427
  Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
  University of Alabama at Birmingham
• RECRUITINGNCT07152834
  Screening for Alpha-1 Antitrypsin Deficiency in Patients With Airway Obstruction
  Muğla Sıtkı Koçman University
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT07193615
  Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
  RenJi Hospital
• RECRUITINGNCT06505603
  PiMZ Longitudinal Cohort (PiMZ Logic)
  Columbia University
• RECRUITINGPHASE1NCT06996756
  Gene Therapy for Alpha 1- Antitrypsin Deficiency
  Weill Medical College of Cornell University
• ACTIVE NOT RECRUITINGPHASE1NCT06738017
  Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
  BioMarin Pharmaceutical
• ENROLLING BY INVITATIONNANCT06892236
  Preparation of IPSC for Cell Gene Editing for the Treatment of AATD
  Fondazione IRCCS Policlinico San Matteo di Pavia

See all trials for Alpha-1-antitrypsin deficiency →